Oxford, UK, 28 March 2018 – Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.
Alex Bronimann joins Emergex as Finance Director. He brings over 20 years’ experience in the healthcare, pharmaceutical, technology, telecoms and manufacturing sectors. Alex’s strengths will contribute to financial strategy, focusing on financing activities, global costing, pricing and oversight of the Company’s finances. He leads day-to-day responsibility for financial controls and reporting, budgeting, forecasting, audit, tax, cash and treasury management.
Prior to Emergex, Alex was Finance Director at OrganOx Ltd, an Oxford University spin-out and start-up medical device company. Previously, Alex was Group CFO and Board Director at Adestra Group and before that he worked for several ‘blue chip’ companies including Vodafone, GE, Dell, Amersham and Cable & Wireless. Alex is a qualified Chartered Accountant.
Natalie Sands also joins Emergex’s new Finance function as Financial Controller. She is responsible for day-to-day financial operations including management reporting, payroll, supporting the audit process, and establishing robust financial policies and procedures.
Natalie has a broad range of experience in commercial finance including at large companies such as Live Nation Entertainment Ltd and Amey Plc. She joins Emergex from Amey Plc, where she was Senior Accountant within the Investments division, which included complex accounting for Special Purpose Vehicle Companies (SPV). Prior to this she was Group Financial Controller for Summit Therapeutics Plc. Natalie is a qualified Chartered Certified Accountant and is a Fellow member of the Association of Chartered Certified Accountants.
Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “Alex and Natalie join Emergex at an exciting time in our growth as we look to advance the development of EMX-001, our universal Flavivirus vaccine candidate, for diseases such as Zika, Dengue and Yellow Fever towards clinical development early next year and our universal Filovirus and Influenza programmes in preclinical development. The new capabilities that Alex and Natalie bring will help support fundraising and ensure that we establish strong financial governance and cost controls as we grow.”
Notes to Editors
About Emergex Vaccines Holding Limited
Emergex Vaccines Holding Limited, a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats such as Zika, Ebola, pandemic flu and antibiotic resistant bacteria.
It has developed a novel and ground-breaking approach to vaccine manufacturing, using 100% synthetic components to activate T-cells of the immune system to destroy virus-infected human cells. It uses unique technologies together with top-notch science to develop and manufacture vaccines much faster and at a fraction of the cost of traditional vaccines.
Emergex is initially focussed on creating an internationally accessible, clinical grade vaccine repository for use by governments, non-governmental organisations and charities, to act as a first line of defence against existing and newly emerging infectious outbreaks. It also plans to develop commercially marketed vaccines in partnership with pharmaceutical companies to generate future licensing and royalty revenue streams.
Emergex is committed to making a positive impact in the communities that are most affected by these infectious outbreaks, where a lack of affordable and effective treatments adversely impacts health and prosperity. Recently it joined the Social Stock Exchange in London, the world’s first regulated exchange dedicated to businesses and investors seeking to achieve a positive social and environmental impact through their activities.
Find out more online at www.emergexvaccines.com.
Sue Charles/ Ashley Tapp
Phone: +44 (0)20 7457 2020